查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2070544

輻射中毒治療市場規模、佔有率、成長、全球產業分析、區域趨勢及2026-2034年預測

Radiation Toxicity Treatment Market Size, Share, Growth, Global Industry Analysis, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

輻射中毒治療市場的成長要素

2025年全球輻射中毒治療市場規模為13億美元，預計將從2026年的13.8億美元成長至2034年的21.7億美元，預測期內（2026-2034年）複合年成長率（CAGR）為5.86%。 2025年，北美市場佔全球主導地位，約佔總營收的50%。這主要歸功於北美地區放射治療的高利用率、先進的腫瘤治療基礎設施以及癌症支持治療的日益普及。

輻射中毒治療包括使用藥物、生物製藥、局部用藥和支持性護理產品來預防、減輕或控制放射治療引起的併發症。常見的放射毒性包括口腔黏膜炎、放射性皮膚炎、口乾、放射性腸炎、放射性食道炎和放射性直腸炎。由於放射治療仍然是全球癌症治療的基石，因此對有效毒性管理方案的需求持續成長。

癌症發生率上升、放射治療手術量增加以及對患者生活品質（QOL）日益重視是推動市場擴張的主要因素。 Stratpharma AG、Flen Health、KeraNetics、Solventum、Soligenix 和 Galera Therapeutics 等領先企業正積極投資於創新的癌症支持治療解決方案。

市場規模及預測

  • 2025年市場規模：13億美元
  • 2026年市場規模：13.8億美元
  • 2034年市場規模預測：21.7億美元
  • 2026-2034年複合年成長率：5.86%

市場趨勢

人們對癌症支持性治療的興趣日益濃厚。

癌症治療中心越來越重視在進行主要癌症治療的同時，提供支持性護理。有效控制放射治療的副作用，能夠幫助患者順利完成治療計劃，進而改善整體治療效果。

針對口腔黏膜炎、放射性皮膚炎和口乾症的特效療法的研發正成為產業發展的重要趨勢。 2026年3月，Soligenix公司公佈了SGX945的進展，該藥物在英國獲得了「有前景的創新藥物」認定，用於治療與放射線治療相關的口腔黏膜炎。

市場促進因素

全球癌症負擔日益加重以及放射療法的廣泛應用

隨著全球癌症患者人數的不斷增加，放射治療的需求也持續成長。放射治療使用量的增加，也導致需要醫療介入的治療相關不利事件發生率上升。

醫療專業人員擴大採用輔助護理產品，以減少治療中斷、提高患者舒適度並改善治療效果。癌症治療設施的擴建和毒性管理意識的提高進一步推動了市場成長。

市場限制因素

已通過核准的高特異性療法數量有限。

儘管需求不斷成長，但由於針對嚴重口腔黏膜炎和放射性皮膚炎等疾病的高效且廣泛認可的治療方法數量有限，市場面臨挑戰。

許多醫療機構仍然依賴基於症狀的治療方法，而不是標靶治療。監管障礙和臨床試驗的挑戰也減緩了新療法的商業化。

市場機遇

針對放射誘發併發症的標靶治療的研發

目前存在著開發特異性針對口腔黏膜炎、放射性皮膚炎和口乾症的創新療法的巨大機會。這些併發症仍然是接受放射治療的患者最常見的副作用之一。

精準診斷和個人化支持治療的進步有望開闢新的成長途徑。諸如毒性預測測試等技術正在幫助臨床醫生識別治療相關併發症高風險患者。

市場挑戰

保險報銷和費用相關障礙

輻射中毒管理產品通常被歸類為輔助治療而非癌症主要治療。因此，其報銷政策因醫療保健系統而異。

醫院和癌症中心的預算限制可能會延遲新輔助治療產品的推出，尤其是在醫療資源仍然有限的新興市場。

細分分析

藥物類別

市場包括：

  • 細胞保護劑
  • 唾液分泌促效劑/促效劑
  • 局部皮質類固醇
  • 局部麻醉劑
  • 用於胃腸道的抗發炎藥物和黏膜保護劑
  • 止痛藥
  • 其他

到2025年，由於唾液腺促效劑/膽鹼能促效劑在治療放射性口乾和唾液腺功能障礙方面應用廣泛，預計將佔市場主導地位。局部皮質類固醇市場預計到2034年將保持強勁成長。

疾病適應症

市場包括：

  • 口腔黏膜炎
  • 放射性皮膚炎
  • 口乾症/唾液腺功能障礙
  • 放射性直腸炎
  • 放射性食道炎
  • 放射性腸炎
  • 其他

到2025年，口腔黏膜炎細分市場將佔最大的市場佔有率，這主要歸因於其在接受放射治療的頭頸癌患者中的高發生率。預計在預測期內，口乾症（口腔乾燥）的市佔率也將顯著成長。

按年齡層

市場包括：

  • 成人
  • 兒童

到 2025 年，由於成人癌症發生率高以及放射療法在成人中的應用，成人市場將佔主導地位。

按類型

市場包括：

  • 品牌
  • 非專利的

到 2025 年，學名藥領域將佔最大的市場佔有率，因為許多輔助療法都有低成本的非專利製劑，並在醫院和癌症中心廣泛使用。

透過行政途徑

市場包括：

  • 口服
  • 外用
  • 腸外
  • 直腸給藥
  • 其他

到 2025 年，由於口服凝膠、錠劑、膠囊和漱口水等產品的廣泛使用，口服領域將引領市場，這些產品具有便利性、患者依從性和毒性管理等優點。

透過分銷管道

市場包括：

  • 醫院藥房
  • 藥局和零售藥房
  • 網路藥房

到 2025 年，醫院藥局領域將佔最大的市場佔有率，因為輻射中毒療法通常會在腫瘤治療中心開立處方和治療。

區域分析

北美洲

北美仍然是最大的區域市場，預計到 2025 年將達到 5 億美元。強大的癌症治療基礎設施、放射線治療的廣泛應用以及先進的支持性護理方案繼續推動市場成長。

預計到 2026 年，美國市場規模約為 5 億美元，約佔全球整體銷售額的 36.03%。

歐洲

預計歐洲將繼續保持穩定成長，並繼續作為第二大區域市場。癌症發生率上升、倖存者護理範圍擴大以及癌症支持性護理服務的改善是推動這一成長的主要因素。

德國和英國繼續為該地區的銷售額做出重大貢獻。

亞太地區

預計到 2026 年，亞太地區市場規模將達到 3.3 億美元。癌症治療基礎設施的快速擴張、癌症發病率的上升以及醫療保健服務的改善正在推動中國、日本、印度和東南亞的市場發展。

拉丁美洲、中東和非洲

預計這些地區將經歷適度成長，這得益於癌症護理基礎設施的擴大、放射治療的可及性的提高以及對輔助性癌症治療的認知的增強。

近期行業趨勢包括許可協議、治療口乾症和口腔粘膜炎的臨床試驗，以及旨在擴大放射誘發併發症治療選擇的放射防護計劃。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要癌症的盛行率（按主要地區/國家分類）
  • 新產品發布：按主要公司分類
  • 輻射中毒技術技術進展概述
  • 產業重大發展動態（合併、收購、合作、新產品發布等）

第5章：2021-2034年全球輻射中毒治療市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • 細胞保護劑
    • 唾液分泌促效劑/膽鹼能藥物
    • 局部皮質類固醇
    • 局部麻醉劑
    • 用於胃腸道的抗發炎藥物和黏膜保護劑
    • 止痛藥
    • 其他
  • 市場分析、洞察與預測：按疾病適應症分類
    • 口腔黏膜炎
    • 放射性皮膚炎
    • 口乾症/唾液腺功能障礙
    • 放射性直腸炎
    • 放射性食道炎
    • 放射性腸炎
    • 其他
  • 市場分析、洞察與預測：按年齡層別分類
    • 兒童
    • 成人
  • 市場分析、洞察與預測：按類型
    • 品牌
    • 非專利的
  • 市場分析、洞察與預測：按給藥途徑
    • 口服
    • 外用
    • 腸外
    • 直腸給藥
    • 其他
  • 市場分析、洞察與預測：按分銷管道分類
    • 醫院藥房
    • 藥局和零售藥房
    • 網路藥房
  • 分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美輻射中毒治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲輻射中毒治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區輻射中毒治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳洲
    • 其他亞太國家

第9章：拉丁美洲輻射中毒治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲輻射中毒治療市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • Stratpharma AG
    • Flen Health
    • KeraNetics, Inc.
    • Solventum
    • Soligenix, Inc.
    • Galera Therapeutics, Inc.
    • Monopar Therapeutics Inc.
    • Soleva Pharma LLC
    • Recordati
    • Partner Therapeutics, Inc.
Product Code: FBI116075

Growth Factors of radiation toxicity treatment Market

The global radiation toxicity treatment market was valued at USD 1.30 billion in 2025 and is projected to grow from USD 1.38 billion in 2026 to USD 2.17 billion by 2034, registering a CAGR of 5.86% during the forecast period (2026-2034). North America dominated the global market in 2025, accounting for approximately 50% of total revenue, driven by high radiotherapy utilization, advanced oncology infrastructure, and increasing adoption of supportive cancer care therapies.

Radiation toxicity treatment includes medications, biologics, topical therapies, and supportive care products used to prevent, reduce, or manage complications arising from radiation therapy. Common radiation-induced toxicities include oral mucositis, radiation dermatitis, xerostomia, radiation enteritis, radiation esophagitis, and radiation proctitis. As radiotherapy remains a cornerstone of cancer treatment worldwide, demand for effective toxicity management solutions continues to increase.

Growing cancer incidence, rising radiotherapy procedures, and increasing emphasis on patient quality of life are key factors supporting market expansion. Leading companies such as Stratpharma AG, Flen Health, KeraNetics, Solventum, Soligenix, and Galera Therapeutics are actively investing in innovative supportive oncology solutions.

Market Size and Forecast

  • 2025 Market Size: USD 1.30 Billion
  • 2026 Market Size: USD 1.38 Billion
  • 2034 Forecast Market Size: USD 2.17 Billion
  • CAGR (2026-2034): 5.86%

Market Trends

Increasing Focus on Supportive Oncology Care

Cancer treatment centers are increasingly prioritizing supportive care alongside primary cancer therapy. Managing radiation-induced side effects effectively helps patients complete treatment schedules without interruptions while improving overall outcomes.

The development of specialized therapies for oral mucositis, radiation dermatitis, and xerostomia is becoming a major industry trend. In March 2026, Soligenix reported progress for SGX945, which received Promising Innovative Medicine designation in the U.K. for oral mucositis associated with chemoradiation therapy.

Market Drivers

Rising Global Cancer Burden and Expanding Radiotherapy Use

The growing number of cancer patients worldwide continues to increase demand for radiotherapy. As radiation therapy usage rises, so does the incidence of treatment-related toxicities requiring medical intervention.

Healthcare providers increasingly adopt supportive care products to reduce treatment interruptions, improve patient comfort, and enhance therapy outcomes. The expansion of oncology treatment facilities and growing awareness regarding toxicity management further support market growth.

Market Restraints

Limited Availability of Highly Specific Approved Therapies

Despite growing demand, the market faces challenges due to the limited availability of highly effective and widely approved treatments for conditions such as severe oral mucositis and radiation dermatitis.

Many healthcare institutions continue to rely on symptom-based management approaches rather than targeted therapies. Regulatory hurdles and clinical trial challenges also delay commercialization of novel treatments.

Market Opportunities

Development of Targeted Therapies for Radiation-Induced Complications

Significant opportunities exist in developing innovative therapies specifically targeting oral mucositis, radiation dermatitis, and xerostomia. These complications remain among the most frequent side effects experienced by radiotherapy patients.

Advancements in precision diagnostics and personalized supportive care solutions are expected to create new growth avenues. Technologies such as predictive toxicity testing are helping clinicians identify patients at higher risk of treatment-related complications.

Market Challenges

Reimbursement and Cost-Related Barriers

Radiation toxicity management products are often classified as supportive therapies rather than primary cancer treatments. As a result, reimbursement policies vary significantly across healthcare systems.

Budget limitations in hospitals and cancer centers may slow adoption of newer supportive care products, particularly in emerging markets where healthcare resources remain constrained.

Segmentation Analysis

By Drug Class

The market is segmented into:

  • Cytoprotective Agents
  • Salivary Stimulants/Cholinergic Agonists
  • Topical Corticosteroids
  • Topical Local Anesthetics
  • Gastrointestinal Anti-inflammatory & Mucosal Protectants
  • Analgesics
  • Others

The salivary stimulants/cholinergic agonists segment dominated the market in 2025 due to widespread use in managing radiation-induced xerostomia and salivary gland dysfunction. The topical corticosteroids segment is projected to witness strong growth through 2034.

By Disease Indication

The market includes:

  • Oral Mucositis
  • Radiation Dermatitis
  • Xerostomia/Salivary Gland Dysfunction
  • Radiation Proctitis
  • Radiation Esophagitis
  • Radiation Enteritis
  • Others

The oral mucositis segment accounted for the largest market share in 2025 due to its high prevalence among head and neck cancer patients receiving radiotherapy. Xerostomia is expected to record notable growth during the forecast period.

By Age Group

Based on age group, the market is categorized into:

  • Adult
  • Pediatric

The adult segment dominated in 2025 owing to the higher incidence of cancer and radiotherapy utilization among adults.

By Type

The market is segmented into:

  • Branded
  • Generics

The generics segment held the largest share in 2025 as many supportive care therapies are available in lower-cost generic formulations widely used in hospitals and cancer centers.

By Route of Administration

The market includes:

  • Oral
  • Topical
  • Parenteral
  • Rectal
  • Others

The oral segment dominated in 2025 due to convenience, patient compliance, and extensive use of oral gels, lozenges, capsules, and mouth rinses for toxicity management.

By Distribution Channel

The market is segmented into:

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

The hospital pharmacies segment accounted for the largest share in 2025 because radiation toxicity treatments are typically prescribed and administered within oncology treatment centers.

Regional Analysis

North America

North America remained the largest regional market, valued at USD 0.50 billion in 2025. Strong cancer treatment infrastructure, widespread radiotherapy adoption, and advanced supportive care protocols continue to drive market growth.

The U.S. market is estimated at approximately USD 0.50 billion in 2026, representing around 36.03% of global revenue.

Europe

Europe is expected to grow steadily and remains the second-largest regional market. Rising cancer incidence, increasing survivorship care, and expanding supportive oncology services are supporting growth.

Germany and the U.K. remain among the key contributors to regional revenue.

Asia Pacific

Asia Pacific is projected to reach USD 0.33 billion in 2026. Rapid expansion of oncology infrastructure, increasing cancer prevalence, and improving healthcare access are driving market development across China, Japan, India, and Southeast Asia.

Latin America and Middle East & Africa

These regions are expected to witness moderate growth supported by expanding cancer care infrastructure, increasing radiotherapy accessibility, and growing awareness regarding supportive oncology treatments.

Competitive Landscape

The global radiation toxicity treatment market is highly consolidated, with major companies focusing on product innovation, clinical development, partnerships, and regulatory approvals.

Key market participants include:

  • Stratpharma AG
  • Flen Health
  • KeraNetics, Inc.
  • Solventum
  • Soligenix, Inc.
  • Galera Therapeutics, Inc.
  • Monopar Therapeutics Inc.
  • Soleva Pharma LLC
  • Recordati
  • Partner Therapeutics, Inc.

Recent industry developments include licensing agreements, clinical trials for xerostomia treatments, oral mucositis therapies, and radiation countermeasure programs designed to expand treatment options for radiation-induced complications.

Conclusion

The radiation toxicity treatment market is expected to experience consistent growth through 2034, driven by rising global cancer incidence, increasing radiotherapy procedures, and growing emphasis on supportive oncology care. The market is benefiting from innovations targeting oral mucositis, radiation dermatitis, and xerostomia, while healthcare providers increasingly recognize the importance of managing treatment-related side effects. Although reimbursement challenges and limited availability of highly specific therapies remain obstacles, ongoing clinical advancements and expanding oncology infrastructure are expected to create substantial opportunities for market participants over the forecast period.

Segmentation By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Region

By Drug Class * Cytoprotective Agents

  • Salivary Stimulants/Cholinergic Agonists
  • Topical Corticosteroids
  • Topical Local Anesthetics
  • Gastrointestinal Anti-inflammatory & Mucosal Protectants
  • Analgesics
  • Others

By Disease Indication * Oral Mucositis

  • Radiation Dermatitis
  • Xerostomia/Salivary Gland Dysfunction
  • Radiation Proctitis
  • Radiation Esophagitis
  • Radiation Enteritis
  • Others

By Age Group * Pediatric

  • Adults

By Type * Branded

  • Generic

By Route of Administration * Oral

  • Topical
  • Parenteral
  • Rectal
  • Others

By Distribution Channel * Hospital Pharmacies

  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region * North America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country)

    • U.S.
    • Canada
  • Europe (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Disease Indication, Age Group, Type, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cancer Indications, By Key Regions/ Countries
  • 4.2. New Product Launches, By Key Players
  • 4.3. Overview of Technological Advancements in Radiation Toxicity Technology
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Radiation Toxicity Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Cytoprotective Agents
    • 5.1.2. Salivary Stimulants/Cholinergic Agonists
    • 5.1.3. Topical Corticosteroids
    • 5.1.4. Topical Local Anesthetics
    • 5.1.5. Gastrointestinal Anti-inflammatory & Mucosal Protectants
    • 5.1.6. Analgesics
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Oral Mucositis
    • 5.2.2. Radiation Dermatitis
    • 5.2.3. Xerostomia/Salivary Gland Dysfunction
    • 5.2.4. Radiation Proctitis
    • 5.2.5. Radiation Esophagitis
    • 5.2.6. Radiation Enteritis
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Type
    • 5.4.1. Branded
    • 5.4.2. Generics
  • 5.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.5.1. Oral
    • 5.5.2. Topical
    • 5.5.3. Parenteral
    • 5.5.4. Rectal
    • 5.5.5. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Drug Stores & Retail Pharmacies
    • 5.6.3. Online Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Radiation Toxicity Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Cytoprotective Agents
    • 6.1.2. Salivary Stimulants/Cholinergic Agonists
    • 6.1.3. Topical Corticosteroids
    • 6.1.4. Topical Local Anesthetics
    • 6.1.5. Gastrointestinal Anti-inflammatory & Mucosal Protectants
    • 6.1.6. Analgesics
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Oral Mucositis
    • 6.2.2. Radiation Dermatitis
    • 6.2.3. Xerostomia/Salivary Gland Dysfunction
    • 6.2.4. Radiation Proctitis
    • 6.2.5. Radiation Esophagitis
    • 6.2.6. Radiation Enteritis
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Type
    • 6.4.1. Branded
    • 6.4.2. Generics
  • 6.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.5.1. Oral
    • 6.5.2. Topical
    • 6.5.3. Parenteral
    • 6.5.4. Rectal
    • 6.5.5. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Drug Stores & Retail Pharmacies
    • 6.6.3. Online Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Radiation Toxicity Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Cytoprotective Agents
    • 7.1.2. Salivary Stimulants/Cholinergic Agonists
    • 7.1.3. Topical Corticosteroids
    • 7.1.4. Topical Local Anesthetics
    • 7.1.5. Gastrointestinal Anti-inflammatory & Mucosal Protectants
    • 7.1.6. Analgesics
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Oral Mucositis
    • 7.2.2. Radiation Dermatitis
    • 7.2.3. Xerostomia/Salivary Gland Dysfunction
    • 7.2.4. Radiation Proctitis
    • 7.2.5. Radiation Esophagitis
    • 7.2.6. Radiation Enteritis
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Type
    • 7.4.1. Branded
    • 7.4.2. Generics
  • 7.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.5.1. Oral
    • 7.5.2. Topical
    • 7.5.3. Parenteral
    • 7.5.4. Rectal
    • 7.5.5. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Drug Stores & Retail Pharmacies
    • 7.6.3. Online Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Italy
    • 7.7.5. Spain
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Radiation Toxicity Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Cytoprotective Agents
    • 8.1.2. Salivary Stimulants/Cholinergic Agonists
    • 8.1.3. Topical Corticosteroids
    • 8.1.4. Topical Local Anesthetics
    • 8.1.5. Gastrointestinal Anti-inflammatory & Mucosal Protectants
    • 8.1.6. Analgesics
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Oral Mucositis
    • 8.2.2. Radiation Dermatitis
    • 8.2.3. Xerostomia/Salivary Gland Dysfunction
    • 8.2.4. Radiation Proctitis
    • 8.2.5. Radiation Esophagitis
    • 8.2.6. Radiation Enteritis
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Type
    • 8.4.1. Branded
    • 8.4.2. Generics
  • 8.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.5.1. Oral
    • 8.5.2. Topical
    • 8.5.3. Parenteral
    • 8.5.4. Rectal
    • 8.5.5. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Drug Stores & Retail Pharmacies
    • 8.6.3. Online Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.7.1. China
    • 8.7.2. Japan
    • 8.7.3. India
    • 8.7.4. Southeast Asia
    • 8.7.5. Australia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Radiation Toxicity Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Cytoprotective Agents
    • 9.1.2. Salivary Stimulants/Cholinergic Agonists
    • 9.1.3. Topical Corticosteroids
    • 9.1.4. Topical Local Anesthetics
    • 9.1.5. Gastrointestinal Anti-inflammatory & Mucosal Protectants
    • 9.1.6. Analgesics
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Oral Mucositis
    • 9.2.2. Radiation Dermatitis
    • 9.2.3. Xerostomia/Salivary Gland Dysfunction
    • 9.2.4. Radiation Proctitis
    • 9.2.5. Radiation Esophagitis
    • 9.2.6. Radiation Enteritis
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Type
    • 9.4.1. Branded
    • 9.4.2. Generics
  • 9.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.5.1. Oral
    • 9.5.2. Topical
    • 9.5.3. Parenteral
    • 9.5.4. Rectal
    • 9.5.5. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Drug Stores & Retail Pharmacies
    • 9.6.3. Online Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Radiation Toxicity Treatment Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Cytoprotective Agents
    • 10.1.2. Salivary Stimulants/Cholinergic Agonists
    • 10.1.3. Topical Corticosteroids
    • 10.1.4. Topical Local Anesthetics
    • 10.1.5. Gastrointestinal Anti-inflammatory & Mucosal Protectants
    • 10.1.6. Analgesics
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Oral Mucositis
    • 10.2.2. Radiation Dermatitis
    • 10.2.3. Xerostomia/Salivary Gland Dysfunction
    • 10.2.4. Radiation Proctitis
    • 10.2.5. Radiation Esophagitis
    • 10.2.6. Radiation Enteritis
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Type
    • 10.4.1. Branded
    • 10.4.2. Generics
  • 10.5. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.5.1. Oral
    • 10.5.2. Topical
    • 10.5.3. Parenteral
    • 10.5.4. Rectal
    • 10.5.5. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Drug Stores & Retail Pharmacies
    • 10.6.3. Online Pharmacies
  • 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Stratpharma AG
    • 11.2.2. Flen Health
    • 11.2.3. KeraNetics, Inc.
    • 11.2.4. Solventum
    • 11.2.5. Soligenix, Inc.
    • 11.2.6. Galera Therapeutics, Inc.
    • 11.2.7. Monopar Therapeutics Inc.
    • 11.2.8. Soleva Pharma LLC
    • 11.2.9. Recordati
    • 11.2.10. Partner Therapeutics, Inc.

List of Tables

  • Figure 1: Global Radiation Toxicity Treatment Market Revenue Breakdown (USD billion) by Region, 2025 & 2034
  • Figure 2: Global Radiation Toxicity Treatment Market Value Share (%), By Drug Class, 2025 & 2034
  • Figure 3: Global Radiation Toxicity Treatment Market Value Share (%), by Disease Indication, 2025 & 2034
  • Figure 4: Global Radiation Toxicity Treatment Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Radiation Toxicity Treatment Market Value Share (%), by Type, 2025 & 2034
  • Figure 6: Global Radiation Toxicity Treatment Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 7: Global Radiation Toxicity Treatment Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 8: Global Radiation Toxicity Treatment Market Value Share (%), by Region, 2025 & 2034
  • Figure 9: North America Radiation Toxicity Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 10: North America Radiation Toxicity Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 11: North America Radiation Toxicity Treatment Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 12: North America Radiation Toxicity Treatment Market Value Share (%), by Disease Indication, 2025
  • Figure 13: North America Radiation Toxicity Treatment Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 14: North America Radiation Toxicity Treatment Market Value Share (%), by Age Group, 2025
  • Figure 15: North America Radiation Toxicity Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 16: North America Radiation Toxicity Treatment Market Value Share (%), by Type, 2025
  • Figure 17: North America Radiation Toxicity Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 18: North America Radiation Toxicity Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 19: North America Radiation Toxicity Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 20: North America Radiation Toxicity Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 21: North America Radiation Toxicity Treatment Market Value (USD billion), by Country, 2025 & 2034
  • Figure 22: North America Radiation Toxicity Treatment Market Value Share (%), by Country, 2025
  • Figure 23: Europe Radiation Toxicity Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 24: Europe Radiation Toxicity Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 25: Europe Radiation Toxicity Treatment Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 26: Europe Radiation Toxicity Treatment Market Value Share (%), by Disease Indication, 2025
  • Figure 27: Europe Radiation Toxicity Treatment Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 28: Europe Radiation Toxicity Treatment Market Value Share (%), by Age Group, 2025
  • Figure 29: Europe Radiation Toxicity Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 30: Europe Radiation Toxicity Treatment Market Value Share (%), by Type, 2025
  • Figure 31: Europe Radiation Toxicity Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 32: Europe Radiation Toxicity Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Europe Radiation Toxicity Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Europe Radiation Toxicity Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Europe Radiation Toxicity Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 36: Europe Radiation Toxicity Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 37: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 38: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 39: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 40: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), by Disease Indication, 2025
  • Figure 41: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 42: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), by Age Group, 2025
  • Figure 43: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 44: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), by Type, 2025
  • Figure 45: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 46: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 47: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 48: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 49: Asia Pacific Radiation Toxicity Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 50: Asia Pacific Radiation Toxicity Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 51: Latin America Radiation Toxicity Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 52: Latin America Radiation Toxicity Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 53: Latin America Radiation Toxicity Treatment Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 54: Latin America Radiation Toxicity Treatment Market Value Share (%), by Disease Indication, 2025
  • Figure 55: Latin America Radiation Toxicity Treatment Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 56: Latin America Radiation Toxicity Treatment Market Value Share (%), by Age Group, 2025
  • Figure 57: Latin America Radiation Toxicity Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 58: Latin America Radiation Toxicity Treatment Market Value Share (%), by Type, 2025
  • Figure 59: Latin America Radiation Toxicity Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 60: Latin America Radiation Toxicity Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 61: Latin America Radiation Toxicity Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 62: Latin America Radiation Toxicity Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 63: Latin America Radiation Toxicity Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 64: Latin America Radiation Toxicity Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 65: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), By Drug Class, 2025 & 2034
  • Figure 66: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), By Drug Class, 2025
  • Figure 67: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), by Disease Indication, 2025 & 2034
  • Figure 68: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), by Disease Indication, 2025
  • Figure 69: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 70: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), by Age Group, 2025
  • Figure 71: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), by Type, 2025 & 2034
  • Figure 72: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), by Type, 2025
  • Figure 73: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 74: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), by Route of Administration, 2025
  • Figure 75: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 76: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), by Distribution Channel, 2025
  • Figure 77: Middle East & Africa Radiation Toxicity Treatment Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 78: Middle East & Africa Radiation Toxicity Treatment Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 79: Global Radiation Toxicity Treatment Market Share (%), by Company, 2025